CureVac NV (LTS:0A9E) Transcripts
Q3 2024 CureVac NV Earnings Call Transcript
Nov 12, 2024
$2.76
(-2.02%)
Earnings
Q4 2023 CureVac NV Earnings Call Transcript
Apr 24, 2024
$2.39
(-8.62%)
Earnings
Q3 2023 CureVac NV Earnings Call Transcript
Nov 14, 2023
$5.72
(+8.24%)
Earnings
CureVac NV at Bank of America Global Healthcare Conference Transcript
May 09, 2023
Q4 2022 CureVac NV Earnings Call Transcript
Apr 25, 2023
$7.65
(-2.92%)
Earnings
CureVac NV Annual Shareholders Meeting Transcript
Mar 28, 2023
CureVac NV Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs Transcript
Jan 06, 2023
Q3 2022 CureVac NV Earnings Call Transcript
Nov 16, 2022
$8.14
(+1.87%)
Earnings
CureVac NV Annual Shareholders Meeting Transcript
Jun 22, 2022
CureVac NV at JMP Securities Life Sciences Conference Transcript
Jun 15, 2022
CureVac NV at Jefferies Healthcare Conference Transcript
Jun 09, 2022
CureVac NV at Bank of America Healthcare Conference Transcript
May 10, 2022
Q4 2021 CureVac NV Earnings Call Transcript
Apr 28, 2022
$15.6
Earnings
Q3 2021 CureVac NV Earnings Call Transcript
Nov 19, 2021
$41.42
(+4.85%)
Earnings
CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript
Oct 12, 2021
CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript
Jul 01, 2021
CureVac NV Updates On Clinical Trial - Corporate Call Transcript
Jun 17, 2021
Q4 2020 CureVac NV Earnings Call Transcript
Apr 15, 2021
Earnings
CureVac N.V. - Special Call Transcript
Feb 05, 2021